A Multicenter, Open-label Trial to Evaluate the Safety of TEV-48125 When Subcutaneously Self-administered in Migraine Patients at the Trial Site and at Home
Latest Information Update: 07 Jan 2022
At a glance
- Drugs Fremanezumab (Primary)
- Indications Migraine
- Focus Adverse reactions; Registrational
- Sponsors Otsuka Pharmaceutical
Most Recent Events
- 26 Jan 2021 Status changed from active, no longer recruiting to completed.
- 02 Sep 2020 Status changed from recruiting to active, no longer recruiting.
- 23 Apr 2020 New trial record